Sequential Amniotic Fluid Thyroid Hormone Changes Correlate with Goiter Shrinkage following in utero Thyroxine...

Area of Science:

• Maternal-fetal medicine
• Endocrinology
• Pharmacology

Background:

• Fetal goiter, often linked to maternal hyperthyroidism treatments like propylthiouracil (PTU), lacks standardized intrauterine management strategies.
• Graves' disease is the predominant cause of fetal goiter, necessitating effective prenatal interventions.
• Existing reports offer limited guidance on optimal timing, dosage, and treatment protocols for fetal goiter.

Observation:

• A case of fetal thyroid goiter diagnosed at 23.6 weeks' gestation due to maternal PTU exposure was managed with intrauterine levothyroxine.
• Amniotic fluid samples were collected during treatment to monitor fetal thyroid hormone levels and antibody changes.
• The study observed an 85% reduction in fetal goiter volume following intrauterine levothyroxine administration.

Findings:

• Intrauterine levothyroxine therapy, with initial doses of 200 μg followed by 400 μg three weeks later, proved effective in reducing fetal goiter volume.
• Amniotic fluid thyroid hormone levels closely correlated with changes in fetal goiter mass, serving as a reliable indicator of treatment efficacy.
• The findings support a potential treatment schedule involving weekly or biweekly therapeutic interventions.

Implications:

• Developing a standardized approach to intrauterine fetal goiter treatment, incorporating fetal goiter size and amniotic fluid hormone monitoring, can enhance therapeutic outcomes.
• Establishing a comprehensive database through standardized amniotic fluid thyroid panels is crucial for determining optimal treatment frequency and timing.
• This research paves the way for improved management protocols for fetal goiter, addressing a critical gap in maternal-fetal medicine.